Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma

Documenti analoghi

• The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
  di: Vivian Jiang, et al.
  Pubblicazione: (2024-06-01)
• Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
  di: Lauren E. Kueffer, et al.
  Pubblicazione: (2021-06-01)
• Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
  di: Raji E Joseph, et al.
  Pubblicazione: (2024-12-01)
• Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
  di: Preetesh Jain, et al.
  Pubblicazione: (2023-10-01)
• Exposure to Therapeutic BTK Inhibitors Induces Phenocopying of Btk29A Mutants in the Fruit Fly Drosophila melanogaster
  di: Noriko Hamada-Kawaguchi, et al.
  Pubblicazione: (2023-06-01)